AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22147903
Drug: Simvastatin/Ezetimibe combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/Ezetimibe combination
Trial: 18050627
Drug: Acupuncture group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture group (n=30) with manual acupuncture stimulation of Ganshu (BL18), Pishu (BL20), Zusanli (ST 36), once daily for 30 days, in addition to diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Trial: 18050627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=24) with diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Trial: 10615719
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (2‐mg or 8‐mg tablets; maximum daily dose 8 mg)
Trial: 10615719
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (racemic D ‐/+ L‐methadone; maximum daily dose 80 mg)
Trial: 8960988
Drug: Intravaginal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal and oral misoprostol (100 micrograms intravaginally followed by 100 micrograms p.o. every 2 h)
Trial: 8960988
Drug: Oxytocin/PGE2 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin/PGE2 gel (PGE2 cervical instillation 6 h before continuous oxytocin infusion)
Trial: 8960988
Drug: Oxytocin/PGE2 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin/PGE2 gel
Trial: 11823757
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg for 7 days, followed by 400 mg for 21 days)
Trial: 2073711
Drug: Metrifonate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 2.5 mg/kg
Trial: 2073711
Drug: Metrifonate 5
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 5 mg/kg
Trial: 2073711
Drug: Metrifonate 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 7.5 mg/kg
Trial: 2073711
Drug: Metrifonate 15
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 15 mg/kg
Trial: 9210002
Drug: Acyclovir treatment
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir treatment
Trial: 25567476
Drug: Subcutaneous methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous methylnaltrexone bromide 12 mg (MNTX group)
Trial: 23135087
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% spray (monotherapy or add-on therapy)
Trial: 15983792
Drug: Methylphenidate 40
RxNorm normalized name: METHYLPHENIDATE 40MG 24HR SA CHEW TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 40 mg
Trial: 16884978
Drug: Morphine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (40 mg)
Trial: 17061994
Drug: Corticosteroid withdrawal
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid withdrawal (1 mg/month)
Trial: 15261314
Drug: Dual-injection technique
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-injection technique (Group 2)
Trial: 15261314
Drug: Single-injection technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection technique (Group 1)
Trial: 11192132
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg + metformin
Trial: 11192132
Drug: Open-label pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label pioglitazone + metformin
Trial: 9359980
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg/day)
Trial: 9291759
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with propofol
Trial: 3937407
Drug: Misoprostol (Mi)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol (Mi) 100 mcg, 4 doses/day
Trial: 28774880
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle
Trial: 21444799
Drug: Cortisol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (20 mg) administered orally 1 h before each treatment session
Trial: 21444799
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally 1 h before each treatment session
Trial: 9576141
Drug: FP 100
RxNorm normalized name: Peanut Allergen-dnfp 100 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 100 microg, twice daily for 8 weeks
Trial: 3103169
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g oral aspirin
Trial: 23680817
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg/day) plus modular CBT for 16 weeks, followed by maintenance escitalopram for 28 weeks
Trial: 23680817
Drug: Escitalopram plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram plus CBT followed by pill placebo
Trial: 8380567
Drug: 72 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 Gy hyperfractionated radiation therapy + BCNU (80 mg/m2 on days 3, 4, 5 of radiation therapy and then every 8 weeks for 1 year)
Trial: 8380567
Drug: 81.6 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81.6 Gy hyperfractionated radiation therapy + BCNU
Trial: 3717993
Drug: Failure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failure to respond to treatment
Trial: 26350485
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injections (control)
Trial: 20575258
Drug: DTaP-Hib vaccine
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-Hib vaccine
Trial: 12093769
Drug: Doppler strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doppler strain rate echocardiography during dobutamine infusion
Trial: 6182343
Drug: Aggressive protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive protocol using adriamycin, cyclophosphamide, vincristine, dacarbazine for remission induction; additional randomized group received high dose β‐interferon.
Trial: 29703286
Drug: Riboflavin administration
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin administration every 1 minute during UV-A exposure at 3mW/cm2
Trial: 7131548
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2 mg)
Trial: 12891248
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg/day)
Trial: 14580034
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injections, dosage 10 to 50 U per site, total dose up to 200 U in the masticatory system, maximum 400 U if other sites included, injection frequency no more than once every 12 weeks.
Trial: 14580034
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections for chronic myofascial trigger points in painful muscles without observable involuntary movements.
Trial: 10734752
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant or antiplatelet agents
Trial: 1534176
Drug: Ondansetron (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (12 mg orally over 24 h)
Trial: 1534176
Drug: Amphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (15 mg orally)
Trial: 24388868
Drug: Budesonide/formoterol (BUD/FM;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (BUD/FM; Symbicort(®)) for maintenance and reliever therapy (SMART group, n=15)
Trial: 18403271
Drug: 10% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% mannitol iv in 1 L 0.9% NaCL for 4 hours for 5 consecutive days
Trial: 16185958
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with porfimer sodium (PORPDT) plus omeprazole
Trial: 9182115
Drug: Netivudine 200
RxNorm normalized name: Netivudine
DrugBank: Netivudine (DB12606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netivudine 200 mg twice daily
Trial: 9182115
Drug: Netivudine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netivudine (50 mg and 100 mg doses also tested)
Trial: 9182115
Drug: Netivudine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netivudine (all doses)
Trial: 1431261
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (AP)
Trial: 1431261
Drug: Acellular diphtheria
RxNorm normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular diphtheria and tetanus toxoids pertussis vaccine (ADTP)
Trial: 6715565
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 and 975 mg, q.i.d.)
Trial: 18481035
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg l-amphetamine
Trial: 24042024
Drug: Non-aspirin NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin NSAIDs
Trial: 22412170
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rTMS and tDCS
Trial: 19254210
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg/day (n=13)
Trial: 1735830
Drug: IVIG infusions
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG infusions
Trial: 9647022
Drug: 2-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day quadruple therapy (omeprazole 40 mg b.i.d., amoxicillin 2.5 g once daily, metronidazole 500 mg t.i.d., bismuth subcitrate 360 mg t.i.d. for 2 days, followed by omeprazole 20 mg once daily for 6 additional days)
Trial: 9647022
Drug: 2-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day quadruple therapy (per-protocol analysis)
Trial: 29071915
Drug: Medication (Budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Budesonide Powder)
Trial: 23410885
Drug: 40,000 IU/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40,000 IU/week oral vitamin D3 for 12 weeks
Trial: 14985215
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg zeaxanthin
Trial: 14985215
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zeaxanthin
Trial: 14985215
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg and 10 mg zeaxanthin
Trial: 15716329
Drug: Olmesartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (40 mg)
Trial: 22653382
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly for 12 weeks (placebo/etanercept group)
Trial: 16103252
Drug: Monitoring group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring group with no therapy in the slow VT zone
Trial: 11815318
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) 400 microg daily
Trial: 1932612
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg SR oxprenolol once every 24 h
Trial: 1932612
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg RR oxprenolol once every 12 h
Trial: 31611499
Drug: Nicardipine intraluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine intraluminal administration in group A (no-touch SVG)
Trial: 31611499
Drug: Nicardipine intraluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine intraluminal administration in group B (conventional preparation)
Trial: 11469941
Drug: Pre-packed chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-packed chloroquine tablets
Trial: 11469941
Drug: Chloroquine syrup
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine syrup
Trial: 10077773
Drug: SBT/ABPC 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBT/ABPC 3 g i.v., b.i.d.
Trial: 10077773
Drug: CTM 1
RxNorm normalized name: CTM 1MG/P-EPHRINE 15MG CHEW TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTM 1 g i.v., b.i.d.
Trial: 3258429
Drug: High voltage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High voltage electrical stimulation (daily from a commercial high voltage generator)
Trial: 28481241
Drug: Galunisertib monotherapy
RxNorm normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib monotherapy
Trial: 28481241
Drug: Lomustine monotherapy
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine monotherapy
Trial: 26202881
Drug: Melatonin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin supplementation (2 mg for 4 consecutive nights)
Trial: 23787118
Drug: Synbiotic yogurt
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic yogurt (200 g/day)
Trial: 18155491
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide (Ca(OH)2) placement after irrigation with 3 mL 17% EDTA and 10 mL 6% sodium hypochlorite (NaOCl)
Trial: 18155491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group irrigated with 10 mL 0.9% saline
Trial: 18155491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group irrigated with 10 mL 6% sodium hypochlorite (NaOCl)
Trial: 17063640
Drug: Reference ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference ibuprofen preparation (400 mg)
Trial: 14668079
Drug: High-dose labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose labetalol (200 mg)
Trial: 14668079
Drug: Low-dose labetalol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose labetalol (100 mg)
Trial: 20973706
Drug: Medication satisfaction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication satisfaction, ADHD symptoms, and HRQL
Trial: 17662509
Drug: Normal hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hospital diet plus 400 mL oral nutritional supplements (106 subjects)
Trial: 16325695
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (epirubicin, cyclophosphamide, and thiotepa supported by peripheral-blood progenitors)
Trial: 16325695
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (four cycles of epirubicin and cyclophosphamide followed by three cycles of accelerated cyclophosphamide, methotrexate, and fluorouracil)
Trial: 9642605
Drug: Antibiotics (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (amoxicillin and erythromycin)
Trial: 793404
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone phosphate 0.1% eyedrops, five times daily for two weeks
Trial: 793404
Drug: Placebo eyedrops,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eyedrops, five times daily for two weeks
Trial: 31651246
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2.5 ml of hyperbaric bupivacaine 0.5% + 0.5 ml normal saline)
Trial: 25292351
Drug: Fluoxetine (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (acute dose)
Trial: 23649281
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-orthodontic treatment)
Trial: 20021921
Drug: Low-dose amlodipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amlodipine + diuretics (group A)
Trial: 20021921
Drug: Low-dose amlodipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amlodipine + telmisartan (group T)
Trial: 16999566
Drug: Drug-related problems
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related problems (DRPs) identified using a hospital adaptation of Dader's method
Trial: 14511080
Drug: Brief psychodynamic-interpersonal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychodynamic-interpersonal therapy (PIT)
Trial: 19680137
Drug: ACEIs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEIs treatment for 6 weeks
Trial: 11895281
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing with 4 subgingival doses of minocycline microspheres over a 6-month period (RP/M)
Trial: 7781496
Drug: Insulin treated
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treated diabetes
Trial: 73062
Drug: (+)-cyanidanol-3 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-cyanidanol-3 (2 g/day)
Trial: 31839392
Drug: Traditional skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional skin preparation
Trial: 17373187
Drug: Biologic agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agents
Trial: 15253689
Drug: Conventional systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional systemic treatments
Trial: 26626430
Drug: IPX066 245-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX066 245-mg LD capsules under fasting conditions
Trial: 26626430
Drug: IPX066 245-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX066 245-mg LD capsules sprinkled on applesauce
Trial: 26626430
Drug: IPX066 245-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX066 245-mg LD capsules after a high-fat, high-calorie meal
Trial: 20960003
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg scopolamine (intravenous)
Trial: 20960003
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg mecamylamine (max. 15 mg; oral)
Trial: 1534476
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen
Trial: 31790890
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g α-lipoic acid (ALA) daily for 6 months
Trial: 17259696
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ALA treatment)
Trial: 24295024
Drug: Tailored Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored Cognitive-Behavioral Therapy (TCBT)
Trial: 24295024
Drug: Standard Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive-Behavioral Therapy (SCBT)
Trial: 17662554
Drug: Mouthwash oral-throat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash oral-throat rinses
Trial: 17662554
Drug: Water oral-throat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water oral-throat rinses
Trial: 15812256
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg od + Hydrochlorothiazide 12.5 mg